Results 91 to 100 of about 306 (101)

Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution? [PDF]

Drug Des Devel Ther
Chatzimichail E, Pfau K, Gatzioufas Z, Panos GD.   +3 more
europepmc   +1 more source

Evaluating biosimilars: safety, efficacy, and regulatory considerations in clinical studies. [PDF]

Int J Clin Pharm
Liu Y, Wang Y, Wang M, Zhai S, Hou C, Sun F, Jian L.   +6 more
europepmc   +1 more source

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency, Small for Gestational Age, and Turner Syndrome in Germany: Data from the PATRO^® Children Study.

Horm Res Paediatr
Partsch CJ, Partsch CJ, Land C, Pfäffle RW, Schwab KO, Sommer H, German PATRO-Board.   +6 more
europepmc   +1 more source

BMI z-score as a prognostic factor for height velocity in children treated with recombinant human growth hormone due to idiopathic growth hormone deficiency. [PDF]

Endocrine
Budzulak J, Majewska KA, Kędzia A.
europepmc   +1 more source

A Regulatory Perspective on Biosimilar Medicines. [PDF]

Pharmaceutics
Cordeiro MA, Vitorino C, Sinogas C, Sousa JJ.   +3 more
europepmc   +1 more source

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. [PDF]

BioDrugs
Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG.   +5 more
europepmc   +1 more source

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings. [PDF]

BioDrugs
Kvien TK, Betteridge N, Brückmann I, Bodenmüller W, Bryn G, Danese S, Gonçalves J, Maravic Z, Thorne C, Wingate L, Cornes P.   +10 more
europepmc   +1 more source